One-quarter of pediatric pre-B-cell leukemias contain the t(1;19) chromosomal translocation, which fuses 5' exons encoding the transactivation domain of the E2A transcription factor gene to 3' exons encoding the putative DNA-binding region of the unusual homeobox gene, PBX1. (Fig. 1) (12, 17) , and producing a family of five E2A-Pbxl fusion proteins (11, 19) . Differential splicing, which affects the carboxyl terminus of Pbxl, accounts for the expression of two major E2A-Pbxl fusion proteins, designated p85E2A-Pbxl and p77E2A-Pbx1 (12). 
The oncogenicity of E2A-Pbxl proteins has been tested thus far in NIH 3T3 fibroblasts. When assayed by focus formation, growth in agar, or contact inhibition in NIH 3T3 cells, the transforming activity of p85E2APbxl is poor and that of p77E2A-Pbxl is moderate. However, NIH 3T3 cells expressing either p85E2APbxl or p77E2A-Pbxl form tumors in nude mice (11) , indicating that both proteins have malignant potential. Although NIH 3T3 transformation assays indicate that E2A-Pbxl proteins are oncogenic, direct induction of acute leukemia, particularly of the B-cell lineage, in mice would be the strongest argument that expression of E2A-Pbxl causes or contributes to the formation of human pre-B ALL containing t (1;19) .
To determine the effects of human E2A-Pbxl proteins on blood cell differentiation, we introduced the major form of E2A-Pbxl, p85E2A-Pbx1, into normal mouse marrow cells by infection with a helper-free E2A-Pbxl recombinant retrovirus (11) . Infection of marrow progenitors with E2A-Pbxl virus did not alter their growth properties in vitro, even when conditions favoring the growth of pre-B cells were used (22) . However, reconstitution of lethally irradiated recipient mice with the same infected progenitors consistently resulted in the development of acute myeloid leukemia (AML). AMLs were monoclonal or biclonal, each expressed high levels of p85E2APbx1, and all grew in culture immediately after explant. Most were dependent on granulocytemacrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3) for growth. These data prove that E2A-Pbxl is a hematopoietic oncogene and reveal that its leukemic potential is not restricted to the pre-B lineage.
MATERIALS AND METHODS
High-titer, helper-free stocks of retrovirus. The cDNA encoding the 85-kDa form of E2A-Pbxl (11) was cloned into the BclI site of the retroviral vector pGD (7) . This vector was transfected into the packaging cell line T-CRE, and a clone (T-24L) expressing 5 x 105 infectious units/ml was identified by screening viral RNA preparations from G418-resistant colonies for maximal hybridization to a PBX1 probe.
Adoptive transfer (bone marrow reconstitution). Marrow isolation, infection with retrovirus, and reconstitution of lethally irradiated recipients were performed precisely as described by Daley et al. (7) . Briefly, 5 mg of 5-fluorouracil (Sigma) was administered to donor BALB/c female mice by tail vein injection. Six days later, marrow was collected from femurs and tibias of 5-fluorouracil-treated mice. Progenitor cells were purified by centrifugation of marrow on discontinuous Ficoll-Paque (Pharmacia) gradients. Four million purified marrow cells were cocultivated with 10 million T-24L fibroblasts for 48 h in the presence of 10% WEHI-3B supernatant as a source of IL-3 and 2 mg of Polybrene per ml. IL-3 stimulates the growth of most multipotent progenitors and is essential to maintain their viability. The T-24L fibroblasts were treated with 5,000 rads of gamma irradiation prior to use to prevent their continued replication and prevent the subsequent injection of mice with transformed NIH 3T3 fibroblasts. variants of the E2A-Pbxl fusion protein result from this DNA rearrangement. The larger one, designated p85E2APbx1, was used for our experiments because it is the most abunda-nt form produced in pre-B ALL cells containing the t(1;19) translocation (11) . aa, amino acids. ered saline (PBS). Eight BALB/c mice were subjected twice, at 4-h intervals, to 455 rads of gamma irradiation to eliminate endogenous hematopoiesis, and each was then reconstituted with 2 x 106 E2A-Pbxl virus-infected marrow cells by tail vein injection. Mice were maintained in microisolator cages and were fed sterile food and acid water for 6 weeks prior to reconstitution and forever thereafter.
Transfer of leukemic cells to secondary recipients. Secondary mice were subjected to a single dose of sublethal radiation (450 rads). A total of 2 x 106 cells derived from specified sources (see Table 2 of each sample were resolved by electrophoresis through 10% polyacrylamide gels and transferred to nitrocellulose. E2A-Pbxl was stained by incubation of filters in affinitypurified, polyclonal rabbit antibodies to Pbxl (10 ,g/ml) followed by incubation in alkaline phosphatase-conjugated, goat anti-rabbit immunoglobulins and reaction with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate toluidinium as described previously (11) .
Immunofluorescence. enlarged spleen (2.5-to 20-fold) ( Fig. 2A and B ; Table 1 ), and most mice contained proliferating blasts in liver or lung. All sick mice exhibited reduced hematocrits (packed erythrocyte volume) that paralleled the degree to which marrow was replaced by tumor cells (Table 1) and contained an increase in peripheral blood leukocytes (1.5-to 36-fold) due to large numbers of myeloblasts and immature neutrophils. Immunofluorescence analysis indicated that all proliferating blasts were myeloid (positive for the myeloid surface antigen Mac-1 and negative for the B-and pre-B-cell surface antigen B220 and the T-and pre-T-cell surface antigen Thy 1.2; data not shown). Clonal analysis based on unique retroviral integration sites demonstrated that all cells comprising each proliferative disorder were either monoclonal or biclonal and contained, at most, two integrated proviruses (unique sites designated A to L in Table 2 ; minor populations of distinct clones are designated in parentheses).
Six of the seven mice contained solid masses of leukemic cells, weighing up to 2.9 g, in nonhematopoietic tissue (Fig.  2B , G, I, K, and L), that were in two cases (HF3 and HF6) composed of a unique cell clone (Table 2 ). These masses appeared to be the mouse cognate of human granulocytic sarcomas (also designated chloromas or myeloblastomas) because they were composed, again, strictly of myeloid cells. In humans, granulocytic sarcoma is a rare myeloid malignancy, accompanying approximately 1% of AMLs, and most often associated with AML or the transition of chronic myeloid leukemia (CML) or myelodysplastic syndrome (MDS) to AML (16) . The mouse granulocytic sarcomas exhibited a wide variation in degree of differentiation (Table  2) , as do their human counterparts (16) . As in human AML (16) , they also grew in diverse locations in diseased mice, including the peritoneal cavity and regions adjacent to the spinal column (Table 1) . Spinal cord compression resulting from their growth is likely to be responsible for the hind limb paralysis observed in mice HF1, HF2, and HF3 because both intradural and epidural spinal compressions resulting from granulocytic sarcomas have been reported to cause paralysis in humans (10, 15) . The mouse granulocytic sarcomas also mimicked their human counterparts by sometimes arising before extensive hematopoietic progression of AML (e.g., mouse HF6).
On the basis of a 30 to 95% abundance of myeloblasts in marrow frequently accompanied by granulocytic sarcomas, these proliferative disorders were diagnosed as AML rather than CML or MDS. Expression of E2A-Pbxl in tumor tissue was analyzed by Western immunoblotting with antibodies against Pbxl. Tumor cells from marrow, spleen, liver, granulocytic sarcomas, and ascites fluid contained amounts of p85E2A-Pbxl comparable to those present in the t(1;19)-containing human pre-B ALL cell line 697 (a subset is represented in Fig. 3A) , strongly suggesting that retrovirusinduced expression of p85E2A-15bx performs an essential role in the genesis of these leukemias.
Consistent with the behavior of AML in mice, E2A-Pbxlassociated AML was transferred efficiently to secondary recipients (Table 1) ; each AML that developed in a secondary recipient was derived from one of the original leukemic donor clones (Table 2 ). (In Table 1 , HF1.1 refers to the secondary recipient of 2 x 106 cells from the primary diseased mouse, HF1.) E2A-Pbxl disease is marked by factor dependence and blocked differentiation. Each AML exhibited variable degrees of differentiation in vivo. This variation was most strongly demonstrated by analyzing granulocytic sarcomas because these solid masses contain essentially only tumor cells. The granulocytic sarcomas exhibited different degrees of differentiation; some consisted almost solely of myeloblasts ( Fig. 2K; Table 2 ), whereas others contained mostly myelocytes and metamyelocytes (Fig. 21) . Partial differentiation of leukemic cells was also evident in the peripheral blood of mouse HF1 (20-fold-elevated leukocyte count; Fig.  2E ) and in the ascites fluid of mouse HF2 (Fig. 2F) . Other AMLs exhibited a phenotype indicative of a stronger block in differentiation at the promyelocyte (HF4; Fig. 2J ) or myeloblast stage (HF3, HF5, and HF7; Fig. 2H , K, and L, respectively).
Cell lines representing original AML clones from each mouse (Table 2) Table 2 ) and all of which contained significant amounts of p85E2A-Pbxl (Fig. 3) tained their myeloid phenotype in culture (Mac-1 positive, Thy 1.2 negative, B220 negative) with the exception of clone G from mouse HF4, which also became strongly Thy 1.2 positive. Each line was tested for its dependence on GM-CSF for growth. In the absence of GM-CSF, clones A, G, and L continued to proliferate whereas clones D, E, F, and J died (Fig. 4) . These data suggest that one of the target cells for transformation by E2A-Pbxl is a GM-CSF-dependent myeloid progenitor. The results also demonstrated that p85E2A-Pbx1 does not substitute fully for the viability or growth-stimulatory functions of GM-CSF. Expression of either p85E2A-Pbx or p77E2A-Pbxl in LyD9 pro-B cells (18) also did not alter their IL-3 dependence, demonstrating that the function of E2A-Pbxl is distinct from that of v-Abl or Bcr-Abl, both of which abrogate IL-3 dependence (5, 6).
A major defect in each AML isolated from marrow proliferate and undergo terminal differentiation to neutrophils and macrophages within 4 weeks of being cultured in 16 U of GM-CSF per ml. None of the AML clones were induced to differentiate by the addition of G-CSF to media containing GM-CSF, nor did G-CSF alone substitute for GM-CSF or induce differentiation in GM-CSFindependent clones. After cultivation in GM-CSF-containing medium for 5 months, each AML maintained expression of E2A-Pbxl at levels comparable to that found in the human pre-B ALL line 697 (Fig. 3C) . Although cells from HF5 initially expressed only p85E Pbxl (Fig. 3A, lanes 10 and 11) , they expressed both full-length p85E2APbx1 and a shorter Pbxl-containing protein after cultivation in vitro for 4 months (Fig. 3C, lane 3) . It is possible that the mutation in this form of E2A-Pbxl contains an activating carboxyl-terminal deletion similar to that which enhances the transforming potential of p77El-Pb1 (11) . DISCUSSION E2A-Pbxl-induced disease was diagnosed as AML on the basis of its (i) myeloid immunologic and histologic phenotype, (ii) high fraction of marrow blasts, (iii) presentation with granulocytic sarcoma, (iv) variable level of circulating myeloid progenitors, (v) ease of transmission to secondary recipients, and (vi) ease of establishment as GM-CSF-dependent cell lines in culture. E2A-Pbxl disease was not diagnosed as CML or MDS. In humans, CML is consistently accompanied by a large increase in the abundance of mature and maturing neutrophils in the periphery. In three cases, HF1, HF2, and HF3, E2A-Pbxl disease was accompanied by substantial increases in circulating neutrophil progenitors that typify CML; however, the rapidly rising leukocyte count in these mice occurred coincident with the growth of granulocytic sarcomas, a high marrow blast fraction, and efficient transplantability of the leukemic clone in secondary mice, arguing that the disease represented AML. In addition, some human AMLs, specifically the M2 subgroup containing the t(8;21) translocation, exhibit substantial neutrophilic differentiation of circulating leukemic cells (1) . The transplantability of E2A-Pbxl disease distinguishes it from the CML-like diseases induced by retrovirus-mediated expression of p210BCrAbl or gpl20v-Fms, which are characterized by a dramatic increase in mature, circulating neutrophils and which are nontransplantable (8, 24) . E2A-Pbxl disease was distinct from MDS, which in humans is characterized by an enlarged spleen in only 20% of cases, a suppressed leukocyte count, and less than 30% blasts in marrow, with cells exhibiting morphologic evidence of abnormal myeloid cell development. In addition, MDS itself is not accompanied by the growth of granulocytic sarcomas, which are Observed in five AML-associated contexts: (i) preceding AML in apparently normal individuals, (ii) accompanying AML, (iii) accompanying blast crisis in CML, (iv) accompanying conversion of MDS to AML, or (v) fully independent of other detectable AML, CML, or MDS (4, 13, 16, 21, (24) (25) (26) . Finally, it is possible that E2A-Pbxl-associated AMLs were preceded either by MDS or by a very brief CML-like phase.
Expression of E2A-Pbxl alone appears insufficient to produce AML. Because E2A-Pbxl itself did not induce factor independence, the lymphokine-independent growth of clones A, G, and L indicates that secondary mutations abrogating factor dependence have probably occurred. These mutations may complement the function of E2A-Pbxl in producing overt AML in these cases. The hypothesis for secondary mutation is also supported by analysis of mouse HF8, which remained asymptomatic 8 months posttransplantation even though its marrow and spleen expressed moderate amounts of p85E2A-Pbxl ( Fig. 3B; One mechanism for the relatively long latency of disease in transplanted mice might be the activation of endogenous helper virus or recombination of the E2A-Pbxl retroviral vector with an endogenous host provirus to generate a myelotrophic helper virus. If this were to happen, one might argue that the AMLs observed in this model were induced by helper virus alone. Two experiments strongly discount this possibility. First, if any of the mouse AMLs contained helper virus, they should produce virions containing the recombinant E2A-Pbxl genomic RNA that could confer G418 resistance upon infected NIH 3T3 cells. Samples (6 ml) of culture supernatants from clones A, E, G, H, J, and L were tested for this activity, and none were positive. Second, we have now demonstrated directly that helper-free virus encoding p85E2A-Pbxl will reproducibly immortalize primary marrow GM-CSF-dependent progenitors within 4 weeks of infection of primary marrow only when these cells are cultivated in the presence of GM-CSF, whereas infection by an equivalent titer of the parental neomycin virus, or helper virus alone, does not result in the outgrowth of myeloblasts (10a Alternatively, the need for mutation of a second gene, such as N-ras, which is activated in a low frequency of childhood ALLs and AMLs (2, 20) , might occur more frequently in the myeloid lineage than it does in the lymphoid lineage in mice.
Finally, marrow from 6-week-old mice may not contain a target cell equivalent to that which undergoes the t(1;19) chromosomal translocation in the generation of pre-B ALL in humans. However, regardless of the reasons that account for the absence of pre-B-cell disease in this mouse model, we postulate that the transforming function of E2A-Pbxl in human pre-B ALL is likely to parallel its transforming function in mouse AML.
